Yi Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yi Zhao has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Zhen Cai
Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
10 shared publications - Jingsong He
Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
9 shared publications Jingsong He
Bone Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
6 shared publicationsFangshu Guan
Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University
5 shared publicationsZhen Cai
Zhejiang University School of Medicine, Hangzhou, Zhejiang, P.R. China
5 shared publicationsDonghua He
Department of Hematology and Bone Marrow Transplantation Center The First Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou Zhejiang China
4 shared publications
Latest Publications
- 10 November 2026
- Published by Wiley in British Journal of Haematology
Orelabrutinib plus R‐ CHOP in patients with newly diagnosed non‐ GCB double‐expressor DLBCL : A single‐arm, phase II study
Summary: Double‐expressor diffuse large B‐cell lymphoma (DE‐DLBCL) patients, defined by co‐expression of MYC proto‐oncogene protein (≥40%) and B‐cell lymphoma 2 protein (≥50%), typically have poor outcomes with the traditional first‐line R‐CHOP regimen. We conducted a multicentre, single‐arm, phase II study to evaluate the efficacy and safety of first‐line orelabrutinib plus R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), designated O‐RCHOP, in patients with non‐germinal centre B‐cell‐like (non‐GCB) DE‐DLBCL. From 19 November 2021 to 6 February 2025, 49 patients were enrolled. With a median follow‐up of 26.6 months, median event‐free survival (EFS), progression‐free survival (PFS) and overall survival (OS) were not reached, and the estimated 2‐year EFS, PFS and OS rates were 82.0% (95% confidence intervals [CIs]: 71.2%–94.3%), 82.0% (95% CI: 71.2%–94.3%) and 97.9% (95% CI: 94.0%–100.0%) respectively. At the end of treatment, the complete response rate was 89.8% (44/49; 95% CI: 77.8%–96.6%), and the objective response rate was 95.9% (47/49; 95% CI: 86.0%–99.5%). Grade ≥3 adverse events (AEs) occurred in 51.0% of patients, with neutropenia (38.8%) being the most common. No patients died because of AEs. Genetic alteration profiling revealed that the frequently mutated genes were Pim‐1 proto‐oncogene, serine/threonine kinase ( PIM1 ; 63.6%), MYD88 innate immune signal transduction adaptor ( MYD88 ; (51.5%) and CD79b molecule ( CD79B ; 48.5%). O‐RCHOP achieved encouraging efficacy with a manageable safety profile in newly diagnosed DE‐DLBCL, supporting its feasibility as a first‐line regimen.
- 10 November 2026
- Published by Wiley in British Journal of Haematology
Orelabrutinib plus R‐ CHOP in patients with newly diagnosed non‐ GCB double‐expressor DLBCL : A single‐arm, phase II study
Summary: Double‐expressor diffuse large B‐cell lymphoma (DE‐DLBCL) patients, defined by co‐expression of MYC proto‐oncogene protein (≥40%) and B‐cell lymphoma 2 protein (≥50%), typically have poor outcomes with the traditional first‐line R‐CHOP regimen. We conducted a multicentre, single‐arm, phase II study to evaluate the efficacy and safety of first‐line orelabrutinib plus R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), designated O‐RCHOP, in patients with non‐germinal centre B‐cell‐like (non‐GCB) DE‐DLBCL. From 19 November 2021 to 6 February 2025, 49 patients were enrolled. With a median follow‐up of 26.6 months, median event‐free survival (EFS), progression‐free survival (PFS) and overall survival (OS) were not reached, and the estimated 2‐year EFS, PFS and OS rates were 82.0% (95% confidence intervals [CIs]: 71.2%–94.3%), 82.0% (95% CI: 71.2%–94.3%) and 97.9% (95% CI: 94.0%–100.0%) respectively. At the end of treatment, the complete response rate was 89.8% (44/49; 95% CI: 77.8%–96.6%), and the objective response rate was 95.9% (47/49; 95% CI: 86.0%–99.5%). Grade ≥3 adverse events (AEs) occurred in 51.0% of patients, with neutropenia (38.8%) being the most common. No patients died because of AEs. Genetic alteration profiling revealed that the frequently mutated genes were Pim‐1 proto‐oncogene, serine/threonine kinase ( PIM1 ; 63.6%), MYD88 innate immune signal transduction adaptor ( MYD88 ; (51.5%) and CD79b molecule ( CD79B ; 48.5%). O‐RCHOP achieved encouraging efficacy with a manageable safety profile in newly diagnosed DE‐DLBCL, supporting its feasibility as a first‐line regimen.
- Open Access
- 21 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1973646
Brentuximab vedotin plus CHP-like versus CHOEP regimen for the first-line treatment of PTCL patients: a multi-center propensity-matched retrospective study
Introduction: The optimal frontline treatment option for Peripheral T-cell lymphomas (PTCLs) has not been completely defined. Methods: To compare the efficacy and safety of brentuximab vedotin (BV) combined with CHP-like regimen (cyclophosphamide, an anthracycline component, and prednisone) and CHOEP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone and etoposide) as first-line treatment for newly diagnosed PTCLs, we used 1:1 optimal propensity score-matching (PSM) to match patients by gender, age, disease stage, bone marrow infiltration, extranodal involvement, Eastern Cooperative Oncology Group performance status, and PTCL subtype, resulting in two cohorts of 45 patients each. Results: With a median follow-up of 27.2 months, the 2-year progression-free survival (PFS) rates were 70.7% (95% confidence interval [CI]: 58.5%-85.5%) and 45.3% (95% CI: 32.7%-62.7%) for the BV plus CHP-like and CHOEP groups, respectively (P = 0.012). The 2-year overall survival (OS) rate was 81.0% (95% CI: 68.8%-95.3%) in the BV plus CHP-like group and 75.1% (95% CI: 62.7%-90.1%) in the CHOEP group (P = 0.550). No significant differences were observed between the two groups in complete remission (CR, P = 0.673) and objective response rate (ORR, P = 0.662) at the end-of-follow-up assessment. The duration of response (DOR) in the BV plus CHP-like group was significantly prolonged compared to the CHOEP group (81.9% vs. 63.0%, P = 0.035). In subgroup analysis stratified by ALK expression, no deaths occurred among the 31 ALK-positive ALCL patients; the 2-year PFS rate was 94.4% versus 76.9% (P = 0.066). Among the 59 non-ALK-positive PTCL patients, no significant differences were observed in OS (P = 0.880) or PFS (P = 0.110). BV plus CHP-like regimen was associated with a lower incidence of hematological toxicities than the CHOEP regimen, both for any-grade and for grade ≥ 3 events. Conclusion: The BV plus CHP-like regimen may improve the PFS, without increasing hematological adverse events. However, this benefit was largely offset in non-ALK-positive PTCL patients, and further validation in larger cohorts is warranted.
- 21 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1973646
Open AccessBrentuximab vedotin plus CHP-like versus CHOEP regimen for the first-line treatment of PTCL patients: a multi-center propensity-matched retrospective study
Introduction: The optimal frontline treatment option for Peripheral T-cell lymphomas (PTCLs) has not been completely defined. Methods: To compare the efficacy and safety of brentuximab vedotin (BV) combined with CHP-like regimen (cyclophosphamide, an anthracycline component, and prednisone) and CHOEP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone and etoposide) as first-line treatment for newly diagnosed PTCLs, we used 1:1 optimal propensity score-matching (PSM) to match patients by gender, age, disease stage, bone marrow infiltration, extranodal involvement, Eastern Cooperative Oncology Group performance status, and PTCL subtype, resulting in two cohorts of 45 patients each. Results: With a median follow-up of 27.2 months, the 2-year progression-free survival (PFS) rates were 70.7% (95% confidence interval [CI]: 58.5%-85.5%) and 45.3% (95% CI: 32.7%-62.7%) for the BV plus CHP-like and CHOEP groups, respectively (P = 0.012). The 2-year overall survival (OS) rate was 81.0% (95% CI: 68.8%-95.3%) in the BV plus CHP-like group and 75.1% (95% CI: 62.7%-90.1%) in the CHOEP group (P = 0.550). No significant differences were observed between the two groups in complete remission (CR, P = 0.673) and objective response rate (ORR, P = 0.662) at the end-of-follow-up assessment. The duration of response (DOR) in the BV plus CHP-like group was significantly prolonged compared to the CHOEP group (81.9% vs. 63.0%, P = 0.035). In subgroup analysis stratified by ALK expression, no deaths occurred among the 31 ALK-positive ALCL patients; the 2-year PFS rate was 94.4% versus 76.9% (P = 0.066). Among the 59 non-ALK-positive PTCL patients, no significant differences were observed in OS (P = 0.880) or PFS (P = 0.110). BV plus CHP-like regimen was associated with a lower incidence of hematological toxicities than the CHOEP regimen, both for any-grade and for grade ≥ 3 events. Conclusion: The BV plus CHP-like regimen may improve the PFS, without increasing hematological adverse events. However, this benefit was largely offset in non-ALK-positive PTCL patients, and further validation in larger cohorts is warranted.
- Open Access
- 13 October 2026
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
Benefit of haploidentical hematopoietic stem cell transplantation for elderly patients with acute myeloid leukemia in first complete remission: A clinical observational study with in-depth time-dependent analysis
Background: The efficacy of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in elderly patients with acute myeloid leukemia (AML) remains poorly defined. Objectives: This study aimed to assess the survival benefit of haplo-HSCT among elderly AML patients compared to chemotherapy. Design: AML patients more than 60 years achieve first complete remission (CR1) following induction chemotherapy and eligible for haplo-HSCT between 2020 and 2023 were included in this retrospective study. Methods: A total of 110 AML patients were divided into two groups according to the treatments after CR1: haplo-HSCT ( n = 32) and no haplo-HSCT ( n = 78; receiving hypomethylating agents-based therapy or chemotherapy) groups. The impact of haplo-HSCT was evaluated using three statistical approaches: (1) a time-dependent Cox proportional hazards model, (2) a multistate model for dynamic prediction, and (3) a super landmark analysis. Results: The median age of enrolled AML patients was 64 years (range, 60 – 71 years). Multivariate time-dependent analysis showed that haplo-HSCT significantly improved overall survival (OS; HR = 0.300, 95%CI 0.103 – 0.879; P = 0.028) and relapse-free survival (RFS; HR = 0.269, 95%CI 0.104 – 0.695; P = 0.007). According to the multistate model, patients who did not undergo haplo-HSCT had only a 7.1% probability of maintaining CR for four years after CR1, with a 57.7% probability of disease recurrence. Furthermore, the super-landmark analysis demonstrated that haplo-HSCT significantly improved both OS (HR = 0.249, 95%CI 0.072 – 0.867; P = 0.029) and RFS (HR = 0.258, 95%CI 0.077 – 0.861; P = 0.028). Conclusion: Haplo-HSCT significantly improves survival and reduces relapse in elderly AML patients who achieve CR1, establishing it as a viable and effective consolidative treatment strategy.
- 13 October 2026
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
Open AccessBenefit of haploidentical hematopoietic stem cell transplantation for elderly patients with acute myeloid leukemia in first complete remission: A clinical observational study with in-depth time-dependent analysis
Background: The efficacy of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in elderly patients with acute myeloid leukemia (AML) remains poorly defined. Objectives: This study aimed to assess the survival benefit of haplo-HSCT among elderly AML patients compared to chemotherapy. Design: AML patients more than 60 years achieve first complete remission (CR1) following induction chemotherapy and eligible for haplo-HSCT between 2020 and 2023 were included in this retrospective study. Methods: A total of 110 AML patients were divided into two groups according to the treatments after CR1: haplo-HSCT ( n = 32) and no haplo-HSCT ( n = 78; receiving hypomethylating agents-based therapy or chemotherapy) groups. The impact of haplo-HSCT was evaluated using three statistical approaches: (1) a time-dependent Cox proportional hazards model, (2) a multistate model for dynamic prediction, and (3) a super landmark analysis. Results: The median age of enrolled AML patients was 64 years (range, 60 – 71 years). Multivariate time-dependent analysis showed that haplo-HSCT significantly improved overall survival (OS; HR = 0.300, 95%CI 0.103 – 0.879; P = 0.028) and relapse-free survival (RFS; HR = 0.269, 95%CI 0.104 – 0.695; P = 0.007). According to the multistate model, patients who did not undergo haplo-HSCT had only a 7.1% probability of maintaining CR for four years after CR1, with a 57.7% probability of disease recurrence. Furthermore, the super-landmark analysis demonstrated that haplo-HSCT significantly improved both OS (HR = 0.249, 95%CI 0.072 – 0.867; P = 0.029) and RFS (HR = 0.258, 95%CI 0.077 – 0.861; P = 0.028). Conclusion: Haplo-HSCT significantly improves survival and reduces relapse in elderly AML patients who achieve CR1, establishing it as a viable and effective consolidative treatment strategy.
- Open Access
- 19 February 2026
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 21 (1)
Prognostic role of whole blood Epstein‑Barr virus DNA load in angioimmunoblastic T-cell lymphoma
The prognostic role of Epstein-Barr virus (EBV) DNA in aggressive angioimmunoblastic T-cell lymphoma (AITL) remains unclear. This study aimed to investigat
- 19 February 2026
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 21 (1)
Open AccessPrognostic role of whole blood Epstein‑Barr virus DNA load in angioimmunoblastic T-cell lymphoma
The prognostic role of Epstein-Barr virus (EBV) DNA in aggressive angioimmunoblastic T-cell lymphoma (AITL) remains unclear. This study aimed to investigat
- Open Access
- 2 February 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (2)
Therapy‐Related Acute Myeloid Leukemia Following Plasma Cell Leukemia: A Case Report and Literature Review
With the improvement of survival in multiple myeloma (MM), therapy‐related acute myeloid leukemia (t‐AML) has emerged as a clinically relevant second primary malignancy (SPM). We report a case of MM evolving into t‐AML after multi‐agent chemotherapy and review the literature on therapy‐related leukemias in MM. We report a case of a patient diagnosed with primary plasma cell leukemia (IgG‐λ type, R‐ISS stage III) who achieved complete remission following maintenance therapy with daratumumab, lenalidomide, and dexamethasone after receiving a treatment regimen based on proteasome inhibitors. The patient progressed to therapy‐related acute myeloid leukemia 18 months later, and we present the clinical features. Additionally, we conducted a literature review. Given the patient's age and debilitated physical condition, treatment with azacitidine combined with venetoclax was administered. Following the treatment, the patient developed grade IV post‐chemotherapy myelosuppression complicated by infection and extensive ischemic stroke. Despite aggressive supportive care, the patient's condition continued to deteriorate and he succumbed in August 2025. This case illustrates the leukemogenic risk of cytotoxic exposure in MM, highlights the adverse genetic profile of therapy‐related AML, and emphasizes the need for vigilant monitoring and preventive strategies in long‐term MM survivors.
- 2 February 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (2)
Open AccessTherapy‐Related Acute Myeloid Leukemia Following Plasma Cell Leukemia: A Case Report and Literature Review
With the improvement of survival in multiple myeloma (MM), therapy‐related acute myeloid leukemia (t‐AML) has emerged as a clinically relevant second primary malignancy (SPM). We report a case of MM evolving into t‐AML after multi‐agent chemotherapy and review the literature on therapy‐related leukemias in MM. We report a case of a patient diagnosed with primary plasma cell leukemia (IgG‐λ type, R‐ISS stage III) who achieved complete remission following maintenance therapy with daratumumab, lenalidomide, and dexamethasone after receiving a treatment regimen based on proteasome inhibitors. The patient progressed to therapy‐related acute myeloid leukemia 18 months later, and we present the clinical features. Additionally, we conducted a literature review. Given the patient's age and debilitated physical condition, treatment with azacitidine combined with venetoclax was administered. Following the treatment, the patient developed grade IV post‐chemotherapy myelosuppression complicated by infection and extensive ischemic stroke. Despite aggressive supportive care, the patient's condition continued to deteriorate and he succumbed in August 2025. This case illustrates the leukemogenic risk of cytotoxic exposure in MM, highlights the adverse genetic profile of therapy‐related AML, and emphasizes the need for vigilant monitoring and preventive strategies in long‐term MM survivors.
- Open Access
- 24 November 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 2154
Epstein-Barr virus: biology, pathogenesis and therapy of lymphomas
Epstein-Barr virus (EBV) remains dormant in host B cells for a long time, and more than 90% of patients are asymptomatically infected. However, some internal factors (such as immune deficiency) or exogenous factors (such as HIV infection, inflammation and hypoxia) can destroy this underlying property and lead to disease development. EBV was originally discovered in association with Burkitt lymphomas and is now etiologically associated with malignant lymphomas of B, T, and NK cell origins. Previous relevant studies have reported that EBV could promote the occurrence and development of lymphomas and affect the prognosis. In fact, the pathogenesis of EBV-associated lymphomas involves different viral gene expression patterns and complex cytogenetic changes. Here, the present study summarizes viral two life cycles, latent modes, the establishment of latency and viral reactivation. We also focus on the occurrence of EBV-related lymphomas, generalize and put forward novel perspectives or innovative solutions for treatments according to these pathogenic mechanisms.
- 24 November 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 2154
Open AccessEpstein-Barr virus: biology, pathogenesis and therapy of lymphomas
Epstein-Barr virus (EBV) remains dormant in host B cells for a long time, and more than 90% of patients are asymptomatically infected. However, some internal factors (such as immune deficiency) or exogenous factors (such as HIV infection, inflammation and hypoxia) can destroy this underlying property and lead to disease development. EBV was originally discovered in association with Burkitt lymphomas and is now etiologically associated with malignant lymphomas of B, T, and NK cell origins. Previous relevant studies have reported that EBV could promote the occurrence and development of lymphomas and affect the prognosis. In fact, the pathogenesis of EBV-associated lymphomas involves different viral gene expression patterns and complex cytogenetic changes. Here, the present study summarizes viral two life cycles, latent modes, the establishment of latency and viral reactivation. We also focus on the occurrence of EBV-related lymphomas, generalize and put forward novel perspectives or innovative solutions for treatments according to these pathogenic mechanisms.
- Open Access
- 22 July 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (7) , 3745-3751
Brentuximab vedotin plus CHP-like regimen for the first-line treatment of PTCL patients: a real-world single center study
To evaluate the efficacy and safety of brentuximab vedotin (BV) combined with a CHP-like regimen (cyclophosphamide, doxorubicin, and prednisone) as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL). We retrospectively analyzed the clinical data of patients with PTCL who received BV in combination with a CHP-like regimen as first-line therapy between January 2021 and October 2023. Fifty patients were included in this study, with a median age of 57 years (rang, 22–86 years). The median number of BV cycles administered was six (range, 2–8 cycles). After a median follow-up of 35.2 months (95% confidence interval [CI], 30.9–39.5), the overall response rate (ORR) was 80%, with 44% of the patients achieving a complete response (CR). In patients with the ALK-positive anaplastic large cell lymphoma (ALCL) subtype, the CR rate was 70.6%. The median progression-free survival (PFS) was 39.7 months (95% CI, 14.7-NA), whereas the median overall survival (OS) was not reached (the 1-year OS rate, 90%). Multivariate analysis indicated that bone marrow infiltration at diagnosis was the only factor that was significantly associated with poor OS. Neutropenia (81.3%) was the most common adverse event, and peripheral neuropathy was observed in 16.7% of patients. This real-world study suggests that BV combined with a CHP-like regimen is an effective and safe first-line treatment for patients with newly diagnosed PTCL.
- 22 July 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (7) , 3745-3751
Open AccessBrentuximab vedotin plus CHP-like regimen for the first-line treatment of PTCL patients: a real-world single center study
To evaluate the efficacy and safety of brentuximab vedotin (BV) combined with a CHP-like regimen (cyclophosphamide, doxorubicin, and prednisone) as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL). We retrospectively analyzed the clinical data of patients with PTCL who received BV in combination with a CHP-like regimen as first-line therapy between January 2021 and October 2023. Fifty patients were included in this study, with a median age of 57 years (rang, 22–86 years). The median number of BV cycles administered was six (range, 2–8 cycles). After a median follow-up of 35.2 months (95% confidence interval [CI], 30.9–39.5), the overall response rate (ORR) was 80%, with 44% of the patients achieving a complete response (CR). In patients with the ALK-positive anaplastic large cell lymphoma (ALCL) subtype, the CR rate was 70.6%. The median progression-free survival (PFS) was 39.7 months (95% CI, 14.7-NA), whereas the median overall survival (OS) was not reached (the 1-year OS rate, 90%). Multivariate analysis indicated that bone marrow infiltration at diagnosis was the only factor that was significantly associated with poor OS. Neutropenia (81.3%) was the most common adverse event, and peripheral neuropathy was observed in 16.7% of patients. This real-world study suggests that BV combined with a CHP-like regimen is an effective and safe first-line treatment for patients with newly diagnosed PTCL.
- Open Access
- 15 May 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9, e70129
Incidence, Prognostic Factors, and Treatment Impact on Survival in Natural Killer/T-Cell Lymphoma: Population-Based Study in the United States
Background: Natural killer/T-cell lymphoma (NKTL) is a rare malignancy of mature natural killer/T-cells, predominantly found in Asian and South/Central American populations, with limited studies conducted in Europe and the United States. Objective: The aim of this study is to present an overview of the incidence rate, demographic and clinical characteristics, treatment options, overall survival (OS), and factors influencing OS of NKTL in the United States. Methods: We used data from the Surveillance, Epidemiology, and End Results 17 database to analyze NKTL cases recorded between 2000 and 2020. In a cohort of 1162 patients with NKTL, we calculated the incidence rates and performed statistical analyses to evaluate OS, the effect of radiotherapy and chemotherapy on survival, and lymphoma-specific survival. Results: The mean annual incidence rate of NKTL in the United States was 0.067 per 100,000, with higher rates observed in men compared to women, and an increase noted with age. However, there has been no significant rise in incidence over recent years. Significant racial disparities were observed, with higher incidence rates in non-Hispanic Asian or Pacific Islanders and Hispanic people. The median survival time for patients with NKTL was 21 months, with a 5-year OS rate of 39.5%, which has shown improvement in recent years. Key independent prognostic factors impacting patient survival included age at diagnosis, clinical stage, nasal type presentation, presence of systemic symptoms, and treatment modality. Patients receiving combined radiotherapy and chemotherapy exhibited the best outcomes, with a median OS of 138 months and a 5-year OS rate of 58%. This survival benefit remained consistent even in patients with stage I/localized nasal type lymphoma, achieving a 5-year OS rate of 73.3%. Conclusions: The incidence of NKTL has remained stable in recent years. Patients with the nasal type generally experience better survival outcomes. The use of combined radiotherapy and chemotherapy appears to enhance survival, though further validation through prospective multicenter clinical trials is necessary.
- 15 May 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9, e70129
Open AccessIncidence, Prognostic Factors, and Treatment Impact on Survival in Natural Killer/T-Cell Lymphoma: Population-Based Study in the United States
Background: Natural killer/T-cell lymphoma (NKTL) is a rare malignancy of mature natural killer/T-cells, predominantly found in Asian and South/Central American populations, with limited studies conducted in Europe and the United States. Objective: The aim of this study is to present an overview of the incidence rate, demographic and clinical characteristics, treatment options, overall survival (OS), and factors influencing OS of NKTL in the United States. Methods: We used data from the Surveillance, Epidemiology, and End Results 17 database to analyze NKTL cases recorded between 2000 and 2020. In a cohort of 1162 patients with NKTL, we calculated the incidence rates and performed statistical analyses to evaluate OS, the effect of radiotherapy and chemotherapy on survival, and lymphoma-specific survival. Results: The mean annual incidence rate of NKTL in the United States was 0.067 per 100,000, with higher rates observed in men compared to women, and an increase noted with age. However, there has been no significant rise in incidence over recent years. Significant racial disparities were observed, with higher incidence rates in non-Hispanic Asian or Pacific Islanders and Hispanic people. The median survival time for patients with NKTL was 21 months, with a 5-year OS rate of 39.5%, which has shown improvement in recent years. Key independent prognostic factors impacting patient survival included age at diagnosis, clinical stage, nasal type presentation, presence of systemic symptoms, and treatment modality. Patients receiving combined radiotherapy and chemotherapy exhibited the best outcomes, with a median OS of 138 months and a 5-year OS rate of 58%. This survival benefit remained consistent even in patients with stage I/localized nasal type lymphoma, achieving a 5-year OS rate of 73.3%. Conclusions: The incidence of NKTL has remained stable in recent years. Patients with the nasal type generally experience better survival outcomes. The use of combined radiotherapy and chemotherapy appears to enhance survival, though further validation through prospective multicenter clinical trials is necessary.
- Open Access
- 23 July 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (14) , e70027
TP53 and KMT2D mutations associated with worse prognosis in peripheral T‐cell lymphomas
There are limited studies on mutation profiling for Peripheral T‐cell lymphomas (PTCL) in the Chinese population. We retrospectively analyzed the clinical and genetic landscape of 66 newly diagnosed Chinese patients. Targeted next‐generation sequencing (NGS) was performed for tissues from these patients. At least one mutation was detected in 60 (90.9%) patients, with a median number of 3 (0–7) mutations, and 32 (48.5%) cases detected with more than 4 mutations. The genes with higher mutation frequencies were TET2, RHOA, DNMT3A, IDH2, TP53, STAT3, and KMT2D respectively. When mutant genes are classified by functional group, the most prevalent mutations are related to epigenetics and signal transduction. IPI ≥2, PIT ≥2, and failure to achieve partial remission (PR) were factors for inferior progression‐free survival (PFS) and overall survival (OS). Multivariate analysis showed TP53 was an adverse factor for PFS (HR, 3.523; 95% CI, 1.262–9.835; p = 0.016), and KMT2D was an adverse factor for OS (HR, 10.097; 95% CI, 1.000–101.953; p = 0.048). Mutation profiling could help differentiate distinct types of PTCL and serve as a useful tool for determining treatment options and prognoses.
- 23 July 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (14) , e70027
Open AccessTP53 and KMT2D mutations associated with worse prognosis in peripheral T‐cell lymphomas
There are limited studies on mutation profiling for Peripheral T‐cell lymphomas (PTCL) in the Chinese population. We retrospectively analyzed the clinical and genetic landscape of 66 newly diagnosed Chinese patients. Targeted next‐generation sequencing (NGS) was performed for tissues from these patients. At least one mutation was detected in 60 (90.9%) patients, with a median number of 3 (0–7) mutations, and 32 (48.5%) cases detected with more than 4 mutations. The genes with higher mutation frequencies were TET2, RHOA, DNMT3A, IDH2, TP53, STAT3, and KMT2D respectively. When mutant genes are classified by functional group, the most prevalent mutations are related to epigenetics and signal transduction. IPI ≥2, PIT ≥2, and failure to achieve partial remission (PR) were factors for inferior progression‐free survival (PFS) and overall survival (OS). Multivariate analysis showed TP53 was an adverse factor for PFS (HR, 3.523; 95% CI, 1.262–9.835; p = 0.016), and KMT2D was an adverse factor for OS (HR, 10.097; 95% CI, 1.000–101.953; p = 0.048). Mutation profiling could help differentiate distinct types of PTCL and serve as a useful tool for determining treatment options and prognoses.
- Open Access
- 2 May 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (9) , e7232
Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China
Background: Comparative investigations evaluating the efficacy of pomalidomide‐based (Pom‐based) versus daratumumab‐based (Dara‐based) therapies in patients with relapsed/refractory multiple myeloma (RRMM) remain scarce, both in randomized controlled trials and real‐world studies.Methods: This retrospective cohort study included 140 RRMM patients treated with Pom‐based or Dara‐based or a combination of pomalidomide and daratumumab (DPd) regimens in a Chinese tertiary hospital between December 2018 and July 2023.Results: The overall response rates (ORR) for Pom‐based (n = 48), Dara‐based (n = 68), and DPd (n = 24) groups were 57.8%, 84.6%, and 75.0%, respectively (p = 0.007). At data cutoff on August 1, 2023, the median progression‐free survival (PFS) was 5.7 months (95% CI: 5.0–6.5) for the Pom‐based group, 10.5 months (5.2–15.8) for the Dara‐based group, and 6.7 months (4.0–9.3) for the DPd group (p = 0.056). Multivariate analysis identified treatment regimens (Dara‐based vs. Pom‐based, DPd vs. Pom‐based) and Eastern Cooperative Oncology Group performance status (ECOG PS) as independent prognostic factors for PFS. In the subgroups of patients aged >65 years, with ECOG PS ≥2, lines of therapy ≥2, extramedullary disease or double‐refractory disease (refractory to both lenalidomide and proteasome inhibitors), the superiority of Dara‐based regimens over Pom‐based regimens was not evident. A higher incidence of infections was observed in patients receiving Dara‐based and DPd regimens (Pom‐based 39.6% vs. Dara‐based 64.7% vs. DPd 70.8%, p = 0.009).Conclusions: In real‐world settings, Pom‐based, Dara‐based, and DPd therapies exhibited favorable efficacy in patients with RRMM. Dara‐based therapy yielded superior clinical response and PFS compared to Pom‐based therapy.
- 2 May 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (9) , e7232
Open AccessClinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China
Background: Comparative investigations evaluating the efficacy of pomalidomide‐based (Pom‐based) versus daratumumab‐based (Dara‐based) therapies in patients with relapsed/refractory multiple myeloma (RRMM) remain scarce, both in randomized controlled trials and real‐world studies.Methods: This retrospective cohort study included 140 RRMM patients treated with Pom‐based or Dara‐based or a combination of pomalidomide and daratumumab (DPd) regimens in a Chinese tertiary hospital between December 2018 and July 2023.Results: The overall response rates (ORR) for Pom‐based (n = 48), Dara‐based (n = 68), and DPd (n = 24) groups were 57.8%, 84.6%, and 75.0%, respectively (p = 0.007). At data cutoff on August 1, 2023, the median progression‐free survival (PFS) was 5.7 months (95% CI: 5.0–6.5) for the Pom‐based group, 10.5 months (5.2–15.8) for the Dara‐based group, and 6.7 months (4.0–9.3) for the DPd group (p = 0.056). Multivariate analysis identified treatment regimens (Dara‐based vs. Pom‐based, DPd vs. Pom‐based) and Eastern Cooperative Oncology Group performance status (ECOG PS) as independent prognostic factors for PFS. In the subgroups of patients aged >65 years, with ECOG PS ≥2, lines of therapy ≥2, extramedullary disease or double‐refractory disease (refractory to both lenalidomide and proteasome inhibitors), the superiority of Dara‐based regimens over Pom‐based regimens was not evident. A higher incidence of infections was observed in patients receiving Dara‐based and DPd regimens (Pom‐based 39.6% vs. Dara‐based 64.7% vs. DPd 70.8%, p = 0.009).Conclusions: In real‐world settings, Pom‐based, Dara‐based, and DPd therapies exhibited favorable efficacy in patients with RRMM. Dara‐based therapy yielded superior clinical response and PFS compared to Pom‐based therapy.